California Public Employees Retirement System Has $184.01 Million Stock Holdings in Cencora, Inc. $COR

California Public Employees Retirement System lowered its stake in Cencora, Inc. (NYSE:COR) by 13.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 588,788 shares of the company’s stock after selling 93,334 shares during the quarter. California Public Employees Retirement System owned approximately 0.30% of Cencora worth $184,014,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of COR. Norges Bank acquired a new position in shares of Cencora during the 2nd quarter worth approximately $695,215,000. Marshall Wace LLP grew its stake in shares of Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after buying an additional 1,672,762 shares in the last quarter. Mizuho Markets Americas LLC increased its holdings in Cencora by 116.4% during the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after buying an additional 1,511,906 shares during the last quarter. Artisan Partners Limited Partnership acquired a new position in Cencora during the second quarter worth $411,888,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Cencora by 528.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after acquiring an additional 1,241,186 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

COR has been the topic of a number of research analyst reports. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Bank of America reduced their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Evercore lowered their price target on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Finally, Wells Fargo & Company raised their price objective on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $399.00.

Cencora Price Performance

Cencora stock opened at $349.69 on Monday. Cencora, Inc. has a 12 month low of $252.49 and a 12 month high of $377.54. The stock’s 50 day moving average is $355.58 and its 200-day moving average is $338.81. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The company has a market capitalization of $68.03 billion, a price-to-earnings ratio of 42.03, a PEG ratio of 1.63 and a beta of 0.68.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.73 earnings per share. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.